JunB gene expression is inactivated by methylation in chronic myeloid leukemia

Blood

Volumn 101, Issue 8, 2003, Pages 3205-3211

  Yang, Ming Yu ^b   Liu, Ta Chih ^b   Chang, Jan Gowth ^b   Lin, Pai Mei ^b   Lin, Sheng Fung ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5' AZA 2' DEOXYCYTIDINE; CYTIDINE DERIVATIVE; CYTOSINE DERIVATIVE; GUANOSINE DERIVATIVE; ONCOPROTEIN; PHOSPHATE; PROTEIN C JUN; UNCLASSIFIED DRUG; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; COMPLEMENTARY DNA; DNA; DRUG DERIVATIVE; TUMOR PROTEIN;

ARTICLE; BLOOD ANALYSIS; CARCINOGENESIS; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; DEMETHYLATION; DNA FLANKING REGION; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INACTIVATION; GENE STRUCTURE; GENETIC CODE; HUMAN; HUMAN CELL; METHYLATION; MUTATIONAL ANALYSIS; ONCOGENE C JUN; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BIOSYNTHESIS; CELL STRAIN K 562; COMPUTER SYSTEM; DNA METHYLATION; DRUG EFFECT; GENETICS; NUCLEOTIDE SEQUENCE; ONCOGENE;

AZACITIDINE; COMPUTER SYSTEMS; CPG ISLANDS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DNA, COMPLEMENTARY; DNA, NEOPLASM; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, JUN; HUMANS; K562 CELLS; LEUKEMIA, MYELOID, CHRONIC; NEOPLASM PROTEINS; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-JUN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0038281349     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-05-1598     Document Type: Article

References (35)

1. Angel P, Karin M. The role of Jun, Fos, and the AP-1 complex in cell proliferation and transformation. Biochim Biophys Acta. 1991;1072:129-157.
2. Mollinedo F, Vaquerizo MJ, Naranjo JR. Expression of c-jun, junB and junD proto-oncogenes in human peripheral-blood granulocytes. Biochem J. 1991;273:477-479.
3. Lord KA, Hoffman-Liegermann B, Liebermann DA. Proto-oncogenes of the fos/jun family of transcription factors are positive regulators of myeloid differentiation. Mol Cell Biol. 1993;13:841-851.
4. Lord KA, Hoffman-Liegermann B, Liebermann DA. Complexity of the immediate early response of myeloid cells to terminal differentiation and growth arrest includes ICAM-1, junB, and histone variants. Oncogene. 1990;5:387-396.
5. Boise LH, Petryniak B, Mao X, et al. The NFAT-1 DNA binding complex in activated T cells contains Fra-1 and junB. Mol Cell Biol. 1993;13:1911-1919.
6. Hsu JC, Bravo R, Taub R. Interaction among LRF-1, junB, c-Jun, and c-Fos define a regulatory program in the G1 phase of liver regeneration. Mol Cell Biol. 1992;12:4654-4665.
7. Saffen DW, Cole AJ, Worley PF, Christy BA, Ryder K, Baraban JM. Convulsant-induced increase in transcription factor messenger RNAs in rat brain. Proc Natl Acad Sci U S A. 1998;85:7795-7799.
8. Ryder K, Lau LF, Nathans D. A gene activated by growth factors is related to the oncogene v-jun. Proc Natl Acad Sci U S A. 1988;85:1487-1491.
9. Wilkinson DG, Bhatt S, Ryseck R-P, Bravo R. Tissue-specific expression of c-jun and jun-B during organogenesis in the mouse. Development. 1989;106:465-471.
10. Chiu R, Angel P, Karin M. Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun. Cell. 1989;59:979-986.
11. Hsu JC, Cressman DE, Taub R. Promoter-specific transactivation and inhibition mediated by JunB. Cancer Res. 1993;53:3789-3794.
12. Schütte J, Viallet J, Nau M, Segal S, Fedorko J, Minna J. jun-B inhibits and c-fos stimulates the transforming and trans-activating activities of c-jun. Cell. 1989;59:987-997.
13. Schorpp-Kistner M, Wang Z-Q, Angel P, Wagner EF. JunB is essential for mammalian placentation. EMBO J. 1999;18:934-948.
14. Schorpp M, Jäger R, Schellander K, et al. The human ubiquitin C promoter directs high ubiquitous expression of transgenes in mice. Nucleic Acids Res. 1996;24:1787-1788.
15. INK4a expression. EMBO J. 2000;19:2969-2979.
16. Bakiri L, Lallemand D, Bossy-Wetzel E, Yaniv M. Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J. 2000;19:2056-2068.
17. Schreiber M, Kolbus A, Piu F, et al. Control of cell cycle progression by c-Jun is p53 dependent. Gene Dev. 1999;13:607-619.
18. Passegué E, Jochum W, Schorpp-Kistner M, Mohle-Steinlein U, Wagner EF. Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking JunB expression in the myeloid lineage. Cell. 2001;104:21-32.
19. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330-1340.
20. Liu TC, Lin SF, Chen TP, Liu HW, Chang JG. Mutation analysis of the ras gene in myelocytic leukemia by polymerase chain reaction and oligonucleotide probes. J Formos Med Assoc. 1991;90:825-830.
21. Lin SF, Liu TC, Chen TP, Chiou SS, Liu HW, Chang JG. Diagnosis of thalassaemia by non-isotope detection of α/β and δ/β mRNA ratio. Br J Haematol. 1994;87:133-138.
22. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821-9826.
23. INK4B gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol. 2001;112:148-154.
24. Phinney DG, Tseng SW, Ryder K. Complex genetic organization of junB: multiple blocks of flanking evolutionarily conserved sequence at the murine and human junB loci. Genomics. 1995;28:228-234.
25. Phinney DG, Keiper CL, Francis MK, Ryder K. Quantitative analysis of the contribution made by 5′-flanking and 3′-flanking sequences to the transcriptional regulation of junB by growth factors. Oncogene. 1994;9:2353-2362.
26. Baylin SB, Herman JG Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998;72:141-196.
27. Robertson KD. DNA methylation, methyltransferase, and cancer. Oncogene. 2001;20:3139-3155.
28. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A. 1994;91:9700-9704.
29. Eads CA, Lord RV, Kurumboor SK, et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res. 2000;60:5021-5026.
30. Dong SM, Kim H-S, Rha S-H, Sidransky D. Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res. 2001;7:1982-1996.
31. Roman-Gomez J, Castillejo JA, Jimenez A, et al. 5′ CpG island hypermethylation is associated with transcriptional silencing of the p21 (CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. Blood. 2002;99:2291-2296.
32. Kelliher MA, Mclaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A. 1990;87:6649-6653.
33. Heisterkamp N, Jenster G, Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature. 1990;15;344:251-253.
34. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the reexpression of genes silenced in cancer. Nat Genet. 1999;21:103-107.
35. Traver D, Akashi K, Weissman IL, Lagass E. Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity. 1998;9:47-57.